On ECHEMI
Home > Drugs > Lunan BETTER Pharmaceutical Co., Ltd.
Lunan BETTER Pharmaceutical Co., Ltd.
  • Founded in:

    2003-12-16
  • Country:

    China China
  • Address:

    No. 209, Hongqi Road, Linyi City
  • Tax NO.:

    91371300756399007K
  • Registered Funds:

    115 million yuan
  • Website:

  • Email:

Related Drugs
Valsartan Hydrochlorothiazide Dispersible Tablets
Valsartan Hydrochlorothiazide is a compound preparation, which consists of valsartan and hydrochlorothiazide. 80/12.5mg: Each tablet contains 80mg of valsartan and 12.5mg of hydrochlorothiazide.
Name Description Content CAS NO. Registered Holders
Valsartan

Not yet clear

More

Not yet clear

80mg 137862-53-4 79
Hydrochlorothiazide

Not yet clear

More

Not yet clear

12.5mg 58-93-5 54
Valsartan Hydrochlorothiazide Tablets
This product is a compound preparation. Each tablet contains 80 mg of valsartan and 12.5 mg of hydrochlorothiazide.
Name Description Content CAS NO. Registered Holders
Valsartan

Angiotensin II receptor antagonist, selectively acts on AT1 receptor subtype, reduces elevated blood pressure, and does not affect heart rate. A single oral dose produces a hypotensive effect within 2 hours, reaches a peak effect within 4 to 6 hours, and the hypotensive effect is maintained for more than 24 hours after taking the medicine. Long-term treatment reaches the maximum hypotensive effect after 2 to 4 weeks and is maintained. Combined use with hydrochlorothiazide significantly enhances the hypotensive effect. Sudden termination of treatment does not cause hypertension rebound or other side effects. Does not affect fasting total cholesterol, triglycerides, blood sugar or uric acid levels.

More

Angiotensin II receptor antagonist, selectively acts on AT1 receptor subtype, reduces elevated blood pressure, and does not affect heart rate. A single oral dose produces a hypotensive effect within 2 hours, reaches a peak effect within 4 to 6 hours, and the hypotensive effect is maintained for more than 24 hours after taking the medicine. Long-term treatment reaches the maximum hypotensive effect after 2 to 4 weeks and is maintained. Combined use with hydrochlorothiazide significantly enhances the hypotensive effect. Sudden termination of treatment does not cause hypertension rebound or other side effects. Does not affect fasting total cholesterol, triglycerides, blood sugar or uric acid levels.

80mg 137862-53-4 79
Hydrochlorothiazide

Thiazide diuretics act mainly at the proximal end of the distal convoluted tubule, inhibiting sodium and chloride co-transport, increasing sodium and chloride excretion, and indirectly reducing plasma volume. By increasing renin activity, aldosterone secretion, and potassium excretion, serum potassium decreases. Combining them with angiotensin II receptor antagonists can reduce potassium loss.

More

Thiazide diuretics act mainly at the proximal end of the distal convoluted tubule, inhibiting sodium and chloride co-transport, increasing sodium and chloride excretion, and indirectly reducing plasma volume. By increasing renin activity, aldosterone secretion, and potassium excretion, serum potassium decreases. Combining them with angiotensin II receptor antagonists can reduce potassium loss.

12.5mg 58-93-5 54
Butenafine hydrochloride spray
Each bottle of this product contains 0.1g of butenafine hydrochloride. Excipients are: ethanol, propylene glycol, polysorbate 80.
Name Description Content CAS NO. Registered Holders
Butenafine hydrochloride

Selectively inhibit fungal squalene epoxidase, interfere with the biosynthesis of ergosterol in the fungal cell wall, affect the lipid metabolism of the fungus, damage or kill the fungal cells, and play a bactericidal and antibacterial role

More

Selectively inhibit fungal squalene epoxidase, interfere with the biosynthesis of ergosterol in the fungal cell wall, affect the lipid metabolism of the fungus, damage or kill the fungal cells, and play a bactericidal and antibacterial role

0.1g 101827-46-7 9
Isosorbide mononitrate
Name Description Content CAS NO. Registered Holders
Isosorbide 5-mononitrate

Extract from the above information

More

Extract from the above information

16051-77-7 23
Diatrizoate
Name Description Content CAS NO. Registered Holders
Diatrizoic Acid Dihydrate

No specific description provided

More

No specific description provided

50978-11-5 11
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.